GeneDx Holdings Corp. (WGS) is a Medical - Healthcare Information Services company in the Healthcare sector, currently trading at $67.46. It has a SharesGrow Score of 64/100, indicating a above average investment profile with 4 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of WGS = $974.26 (+1344.2% from the current price, the stock appears undervalued). Analyst consensus target is WGS = $158 (+133.5% upside).
Valuation: WGS trades at a trailing Price-to-Earnings (P/E) of -77.7 (S&P 500 average ~25).
Financials: revenue is $428M, +25.7%/yr average growth. Net income is $21M (loss), growing at +66%/yr. Net profit margin is -4.9% (negative). Gross margin is 69.7% (+81.1 pp trend).
Balance sheet: total debt is $152M against $308M equity (Debt-to-Equity (D/E) ratio 0.49, conservative). Current ratio is 2.46 (strong liquidity). Debt-to-assets is 26.6%. Total assets: $570M.
Analyst outlook: 10 / 11 analysts rate WGS as buy (91%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 100/100 (Pass), Past 0/100 (Fail), Health 67/100 (Partial), Moat 70/100 (Pass), Future 100/100 (Pass), Income 10/100 (Fail).
